Brief: Newbury Pharmaceuticals Q3 EBITDA Loss Widens To SEK 7.9 Mln
July 10 (Reuters) - Newbury Pharmaceuticals AB
NEWBRY.ST :
* Q3 NET REVENUE WAS SEK 1.4 MILLION VERSUS SEK 5.7 MILLION
YEAR
AGO
* Q3 EBITDA LOSS SEK 7.9 MILLION VERSUS LOSS SEK 3.9 MILLION
YEAR
AGO
Source text for Eikon: ID:nMFNbPBTg9
Further company coverage: NEWBRY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Newbury Pharmaceuticals AB
See all newsBrief: Newbury Secures Hospital Portfolio Rights In Iraq
Brief: Newbury Signs Licence And Supply Deal For Guanfacine
Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln